Comparative Pharmacology
Head-to-head clinical analysis: EMPAGLIFLOZIN AND LINAGLIPTIN versus NESINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMPAGLIFLOZIN AND LINAGLIPTIN versus NESINA.
EMPAGLIFLOZIN AND LINAGLIPTIN vs NESINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormones (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon levels.
Inhibitor of dipeptidyl peptidase-4 (DPP-4), preventing inactivation of incretin hormones (GLP-1, GIP), thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner.
10 mg empagliflozin / 5 mg linagliptin orally once daily
25 mg orally once daily.
None Documented
None Documented
Empagliflozin: terminal half-life ~12.4 hours, allowing once-daily dosing. Linagliptin: terminal half-life ~113-131 hours due to saturable binding to DPP-4, enabling once-daily dosing despite short plasma half-life.
Terminal elimination half-life: 12.4–26.1 hours (mean ~21 hours); supports once-daily dosing
Empagliflozin: 54% excreted unchanged in urine (renal), 41% in feces (biliary/fecal). Linagliptin: 80% excreted unchanged in feces via enterohepatic circulation, <5% in urine.
Renal: 87% (75% as unchanged drug, 12% as inactive metabolites); Fecal: <1%
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor